Skip to main content
    P

    Protagonist Therapeutics Inc (PTGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $130.95
    -3.43 (-2.55%)

    Market Cap: $8.55B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Protagonist Therapeutics Inc (PTGX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Protagonist Therapeutics reported revenue of $46.02M for the fiscal year ended Dec 31, 2025, down 89.4% from the year before. That year, net income was -$130.15M with a net margin of -282.8%, operating cash flow was $57.67M and free cash flow was $56.08M. The quarter ended Sep 30, 2026 had revenue of $274.41M and net income of $220.01M.

    Revenue and Margins

    Over the 8 years to Dec 2025, revenue grew from $20.06M, a compound annual rate of 10.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$46.02M-89.4%100.0%-343.6%-282.8%
    Dec 2024$434.43M+624.1%100.0%58.2%63.3%
    Dec 2023$60.00M+125.7%100.0%-156.1%-131.6%
    Dec 2022$26.58M-2.8%100.0%-494.2%-479.3%
    Dec 2021$27.36M-4.4%100.0%-460.0%-458.9%
    Dec 2020$28.63M+12293.1%100.0%-225.4%-231.1%
    Dec 2019$231.00K-99.3%100.0%-34857.6%-33414.3%
    Dec 2018$30.93M+54.1%100.0%-136.7%-125.9%
    Dec 2017$20.06MN/A100.0%-188.9%-184.2%
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$46.02M$434.43M$60.00M$26.58M$27.36M$28.63M$231.00K$30.93M$20.06M$0
    Gross profit$46.02M$434.43M$60.00M$26.58M$27.36M$28.63M$231.00K$30.93M$20.06M$0
    Research and development$159.29M$138.13M$120.16M$126.22M$126.01M$74.51M$65.00M$59.50M$46.18M$25.70M
    Operating income-$158.13M$252.84M-$93.65M-$131.37M-$125.84M-$64.52M-$80.52M-$42.27M-$37.90M-$32.67M
    Net income-$130.15M$275.19M-$78.95M-$127.39M-$125.55M-$66.15M-$77.19M-$38.92M-$36.96M-$37.18M
    EBITDAN/AN/AN/A-$128.63M-$121.39M-$61.80M-$78.59M-$41.56M-$36.81MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$274.41M$213.47M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M$4.67M$4.17M$254.95M$60.00M
    Gross profit$273.31M$213.47M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M$4.67M$4.17M$254.95M$60.00M
    Operating income$218.33M$158.77M-$3.65M-$50.35M-$46.42M-$42.04M-$19.31M$126.78M-$41.45M-$38.79M$206.31M$23.05M
    Net income$220.01M$162.85M$3.78M-$44.38M-$39.34M-$34.77M-$11.65M$131.67M-$33.21M-$30.62M$207.34M$27.34M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.28M by $126.11M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$668.19M$744.73M$357.95M$247.93M$347.69M$324.47M$154.92M$139.47M$163.73M$93.99M
    Current assets$577.57M$591.64M$355.58M$243.08M$340.74M$315.61M$145.31M$137.50M$150.95M$83.24M
    Cash and equivalents$128.39M$97.25M$186.73M$125.74M$123.67M$117.36M$33.01M$82.23M$106.03M$21.08M
    Total liabilities$53.48M$69.43M$21.27M$32.32M$47.67M$44.86M$74.95M$26.96M$43.10M$6.43M
    Short-term debt$2.28M$510.00K$1.14M$2.52M$2.20M$1.46M$1.26M$1.06MN/AN/A
    Long-term debtN/AN/AN/AN/AN/A$0$9.79MN/A$0$0
    Shareholder equity$614.71M$675.29M$336.68M$215.61M$300.02M$279.61M$79.96M$112.52M$120.63M$87.56M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.15B$885.54M$697.46M$669.89M$701.69M$718.01M$742.13M$744.73M$603.86M$614.63M$629.28M$357.95M
    Total liabilities$61.64M$44.00M$41.99M$55.19M$56.25M$49.99M$53.08M$69.43M$71.94M$73.31M$68.83M$21.27M
    Cash and equivalents$498.30M$420.08M$193.71M$128.39M$113.71M$168.54M$139.65M$97.25M$131.12M$355.64M$172.57M$186.73M
    Shareholder equity$1.08B$841.54M$655.47M$614.71M$645.44M$668.02M$689.05M$675.29M$531.91M$541.32M$560.44M$336.68M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 97.2% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$57.67M$184.15M-$70.24M-$108.14M-$107.86M-$72.48M-$41.53M-$49.95M$3.87M-$29.97M
    Capital expenditures$1.59M$1.35M$609.00K$795.00K$1.10M$471.00K$967.00K$486.00K$666.00K$347.00K
    Free cash flow$56.08M$182.80M-$70.84M-$108.93M-$108.97M-$72.95M-$42.49M-$50.43M$3.21M-$30.32M
    Investing cash flow-$49.33M-$299.48M-$39.26M$91.47M-$15.86M-$90.97M-$53.71M$2.21M$15.82M-$59.33M
    Financing cash flow$22.86M$25.85M$170.48M$18.84M$129.92M$247.63M$46.04M$24.11M$65.55M$106.31M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$23.22M$219.05M-$48.94M-$36.98M-$1.94M-$28.78M$125.36M-$29.18M-$27.86M$268.62M-$27.43M$16.96M
    Capital expenditures$237.00K$168.00K$215.00K$144.00K$88.00K$813.00K$545.00K$310.00K$775.00K$28.00K$242.00K$19.00K
    Free cash flow-$23.46M$218.88M-$49.16M-$37.12M-$2.02M-$29.59M$124.82M-$29.49M-$28.64M$268.59M-$27.67M$16.94M
    Last 12 quarters

    Frequently Asked Questions About PTGX

    What is Protagonist Therapeutics' annual revenue?

    Protagonist Therapeutics reported revenue of $46.02M for the fiscal year ended Dec 31, 2025.

    How fast is Protagonist Therapeutics' revenue growing?

    Revenue was down 89.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.1%.

    Is Protagonist Therapeutics profitable?

    No. Protagonist Therapeutics reported net income of -$130.15M for the fiscal year ended Dec 31, 2025, with a net margin of -282.8%.

    How much free cash flow does PTGX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $57.67M minus capital expenditures of $1.59M produced free cash flow of $56.08M.

    How much debt does Protagonist Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.28M and cash and equivalents of $128.39M.